Recruiting

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT05285891

Conditions

Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Ocrelizumab

Placebo for Ocrelizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information